Cancer panels use next generation sequencing (NGS) technology to target specific genes or mutations that have established relevancy to a particular cancer phenotype. NGS facilitates sequencing of large genomic regions, high numbers of genes, and/or high numbers of samples in a single, efficient and cost-effective assay. In addition, NGS provides significantly higher sensitivity than traditional techniques, which permits the discovery of rare somatic mutations, many of which have been identified as important cancer drivers.
Azenta Life Sciences, formerly GENEWIZ offers several cancer panels to provide a complete solution from experimental design to advanced bioinformatics analysis. Each panel can be combined with any of our genomics, transcriptomics, proteomics, and epigenomics services for a multiomics approach, providing crucial insights into human cancer profiles and defining patterns that would have remained unseen and incomplete with just a single assay.
Azenta’s most comprehensive cancer panel, our pan-cancer panel offers coverage of all exons for 634 known tumor suppressors and oncogenes. The panel can be easily multiplexed to accommodate studies of virtually any size and is ideal for biomarker discovery and validation, as well as patient stratification.
Azenta OncoGxOne™ Discovery cancer panels provide comprehensive genomic analysis for cancer research, biomarker discovery, and patient stratification for clinical discovery. These assays provide thorough assessments of 150 - 400 cancer genes of interest utilizing 19 distinct gene panels, each of which assays a specific cancer (organ) type.
Hotspot cancer panels assay multiple cancer types with a single gene panel to target well-characterized, small regions of known cancer genes (~48 genes). The small target region size produces a high depth of sequencing coverage per sample, even when multiplexing, to provide a cost-effective and efficient method for discovering rare somatic mutations.
||Azenta Pan-Cancer Panel||GENEWIZ OncoGxOneTM
Discovery Cancer Panels
Amplicon Cancer Panel
|Sequencing Platform||Illumina MiSeq or HiSeq||Illumina MiSeq or HiSeq||Illumina MiSeq|
|Cancer Types Assayed||Single gene panel assay for multiple cancer types
||19 distinct gene panels, each assays a specific cancer (organ) type||Single gene panel assays multiple cancer types|
|Genes Covered||634||≈150 - 400||48|
|Genomic Variation Detection||
|Target Regions||≈ 2 Mb, consisting of exons and targeted promoter regions||≈ 2 - 5.4 Mb, consisting of all exons, UTRs, and relevant intron regions||≈35 Kb, consisting of mutational hot spots|
|Average Depth||>100x*||> 100x*||> 100x*|
|Target Enrichment||Twist Targeted Enrichment||Agilent SureSelect Targeted Enrichment||Illumina Targeted Amplicon Sequencing|
|DNA Input||> 100 ng||> 100 ng||> 250 ng|
Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.
In this co-hosted webinar with Twist Bioscience, learn how researchers design custom panels to sequence deeply and efficiently into regions, genes, and organisms of interest, as well as gain a greater understanding on how targeted sequencing can be combined with the latest transcriptomics and proteomics tools to reveal even more insights.
Azenta is a certified service provider for Illumina NGS platforms and the PacBio Sequel. Please visit our NGS Platforms page for more information.